Incorporation of Protein Induced by Vitamin K Absence or Antagonist-II Into Transplant Criteria Expands Beneficiaries of Liver Transplantation for Hepatocellular Carcinoma

Zhejiang University

Status: Completed

Conditions: Cancer of Liver

Treatments: Other: No intervention

Study type: Observational

Funder types: Other

Identifiers

NCT05907772

CT2023-ZJU-OBS1

Details and patient eligibility

About

This is a multi-center study in China to investigate the role of PIVKA-II in HCC recipient selection and prognostic stratification by analyzing the data of 522 recipients with HCC registered in the China Liver Transplant Registry.

Enrollment: 522 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The HCC patients received LT with pre-operative PIVKA-II records performed from January 2015 to December 2020, whose clinicopathological data were registered in the CLTR.

Exclusion criteria

• (1) patients who received split LT or simultaneous transplantation, (2) patients who received re-transplantation, (3) patients with macroscopic portal vein tumor thrombosis or other macrovascular invasion, (4) patients with incomplete follow-up or incomplete important parameters records.

Trial design

522 participants in 2 patient groups

Recipients with preoperative PIVKA-II≤240mAU/mL

Treatment:

Other: No intervention

Recipients with preoperative PIVKA-II>240mAU/mL

Treatment:

Other: No intervention